A Ligand-and-structure Dual-driven Deep Learning Method for the Discovery of Highly Potent GnRH1R Antagonist to treat Uterine Diseases

• URL: http://arxiv.org/abs/2207.11547v1
• Date: Sat, 23 Jul 2022 16:04:54 GMT
• Title: A Ligand-and-structure Dual-driven Deep Learning Method for the Discovery of Highly Potent GnRH1R Antagonist to treat Uterine Diseases
• Authors: Song Li, Song Ke, Chenxing Yang, Jun Chen, Yi Xiong, Lirong Zheng, Hao Liu, and Liang Hong
• Abstract summary: Gonadotrophin-releasing hormone receptor (GnRH1R) is a promising therapeutic target for the treatment of uterine diseases. To fill this gap, we aim to develop a deep learning-based framework to facilitate the discovery of a new orally active small-molecule drug targeting GnRH1R with desirable properties.
• Score: 12.616493352225909
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Gonadotrophin-releasing hormone receptor (GnRH1R) is a promising therapeutic target for the treatment of uterine diseases. To date, several GnRH1R antagonists are available in clinical investigation without satisfying multiple property constraints. To fill this gap, we aim to develop a deep learning-based framework to facilitate the effective and efficient discovery of a new orally active small-molecule drug targeting GnRH1R with desirable properties. In the present work, a ligand-and-structure combined model, namely LS-MolGen, was firstly proposed for molecular generation by fully utilizing the information on the known active compounds and the structure of the target protein, which was demonstrated by its superior performance than ligand- or structure-based methods separately. Then, a in silico screening including activity prediction, ADMET evaluation, molecular docking and FEP calculation was conducted, where ~30,000 generated novel molecules were narrowed down to 8 for experimental synthesis and validation. In vitro and in vivo experiments showed that three of them exhibited potent inhibition activities (compound 5 IC50 = 0.856 nM, compound 6 IC50 = 0.901 nM, compound 7 IC50 = 2.54 nM) against GnRH1R, and compound 5 performed well in fundamental PK properties, such as half-life, oral bioavailability, and PPB, etc. We believed that the proposed ligand-and-structure combined molecular generative model and the whole computer-aided workflow can potentially be extended to similar tasks for de novo drug design or lead optimization.

Related papers

• Structure-Aware Compound-Protein Affinity Prediction via Graph Neural Network with Group Lasso Regularization [11.595051456139021]
  We build end-to-end explainable machine learning models for structure-activity relationship (SAR) modeling for compound property prediction.<n>We implement graph neural network (GNN) methods to obtain atom-level feature information and predict compound-protein affinity.<n>We also utilize group lasso and sparse group lasso to prune and highlight molecular subgraphs and enhance the structure-specific model explainability.
  arXiv  Detail & Related papers  (2025-07-04T06:12:18Z)
• DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization [53.27954325490941]
  Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives. This research introduces a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model.
  arXiv  Detail & Related papers  (2025-02-11T04:00:21Z)
• DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback [0.0]
  DrugGen is an enhanced model based on the DrugGPT structure. It is fine-tuned on approved drug-target interactions and optimized with proximal policy optimization. By producing high-quality small molecules, DrugGen provides a high-performance medium for advancing pharmaceutical research and drug discovery.
  arXiv  Detail & Related papers  (2024-11-20T01:21:07Z)
• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced hERG Liability [0.0]
  We present CardioGenAI, a machine learning-based framework for re-engineering both developmental and commercially available drugs for reduced hERG activity. We applied the complete framework to pimozide, an FDA-approved antipsychotic agent, and generated 100 refined candidates. We envision that this method can effectively be applied to developmental compounds exhibiting hERG liabilities to provide a means of rescuing drug development programs that have stalled due to hERG-related safety concerns.
  arXiv  Detail & Related papers  (2024-03-12T13:12:24Z)
• Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning [0.0]
  Multiple sclerosis (MS) is a debilitating neurological disease affecting nearly one million people in the United States. Siponimod, a ligand of S1PR1, was approved by the FDA in 2019 for MS treatment, but there is a demonstrated need for better therapies. This study demonstrates that machine learning can accelerate the drug discovery process and reveal new insights into protein-drug interactions.
  arXiv  Detail & Related papers  (2023-07-29T17:58:47Z)
• State-specific protein-ligand complex structure prediction with a multi-scale deep generative model [68.28309982199902]
  We present NeuralPLexer, a computational approach that can directly predict protein-ligand complex structures. Our study suggests that a data-driven approach can capture the structural cooperativity between proteins and small molecules, showing promise in accelerating the design of enzymes, drug molecules, and beyond.
  arXiv  Detail & Related papers  (2022-09-30T01:46:38Z)
• Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model [4.815696666006742]
  Structure-based de novo method can overcome the data scarcity of active by incorporating drug-target interaction into deep generative architectures. Here, we demonstrate a widely used and fast protein sequence-based reinforcement learning model for drug discovery. As a proof of concept, the RL model was utilized to design molecules for four targets.
  arXiv  Detail & Related papers  (2022-08-14T10:41:52Z)
• Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework [47.14853881703749]
  We demonstrate the broad utility of a single deep generative framework toward discovering novel drug-like inhibitor molecules. To perform target-aware design, the framework employs a target sequence-conditioned sampling of novel molecules from a generative model. The most potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with broad-spectrum activity against several SARS-CoV-2 variants.
  arXiv  Detail & Related papers  (2022-04-19T17:59:46Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics [109.70543391923344]
  CLaSS (Controlled Latent attribute Space Sampling) is an efficient computational method for attribute-controlled generation of molecules. We screen the generated molecules for additional key attributes by using deep learning classifiers in conjunction with novel features derived from atomistic simulations. The proposed approach is demonstrated for designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency.
  arXiv  Detail & Related papers  (2020-05-22T15:57:58Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.